Art. -Nr.: HY-13301

MPC-3100

Kundenbewertung

Based on 1 Customer Validation

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.4%
CAS. Nr.: 958025-66-6
Formel: C₂₂H₂₅BrN₆O₄S
Molecular Weight:549.44

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

MPC-3100 Chemical Structure

CAS. Nr.: 958025-66-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of Hsp90 with potential antineoplastic activity^[1].

Alle HSP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.77 μM Compound: 28g, MPC-3100	Cytotoxicity against human A549 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human A549 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
BT-474	IC₅₀	0.55 μM Compound: 28g, MPC-3100	Cytotoxicity against human BT474 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human BT474 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
DU-145	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in DU145 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method Inhibition of human HSP90 in DU145 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method	[PMID: 22913511]
DU-145	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in DU145 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method Inhibition of human HSP90 in DU145 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method	[PMID: 22913511]
DU-145	IC₅₀	0.53 μM Compound: 28g, MPC-3100	Cytotoxicity against human DU145 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human DU145 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
HCT-116	IC₅₀	0.06 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in HCT116 cells expressing Her2 gene assessed as degradation of Her2 after 4 hrs by luciferase reporter gene assay Inhibition of human HSP90 in HCT116 cells expressing Her2 gene assessed as degradation of Her2 after 4 hrs by luciferase reporter gene assay	[PMID: 22913511]
HCT-116	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in HCT116 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method Inhibition of human HSP90 in HCT116 cells assessed as degradation of Akt incubated for 24 hrs by Western blot method	[PMID: 22913511]
HCT-116	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in HCT116 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method Inhibition of human HSP90 in HCT116 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method	[PMID: 22913511]
HCT-116	IC₅₀	0.54 μM Compound: 28g, MPC-3100	Cytotoxicity against human HCT116 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human HCT116 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
HT-29	IC₅₀	0.42 μM Compound: 28g, MPC-3100	Cytotoxicity against human HT-29 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human HT-29 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
LNCaP	IC₅₀	0.51 μM Compound: 28g, MPC-3100	Cytotoxicity against human LNCAP cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human LNCAP cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
MV4-11	IC₅₀	0.25 μM Compound: 28g, MPC-3100	Cytotoxicity against human MV4-11 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human MV4-11 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
NCI/ADR-RES	IC₅₀	4.3 μM Compound: 28g, MPC-3100	Cytotoxicity against human NCI-ADR-RES cells overexpressing P-gp 1 assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human NCI-ADR-RES cells overexpressing P-gp 1 assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
NCI-H69	IC₅₀	0.15 μM Compound: 28g, MPC-3100	Cytotoxicity against human NCI-H69 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human NCI-H69 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
NCI-N87	IC₅₀	0.1 μM Compound: 28g, MPC-3100	Inhibition of human HSP90 in NCI-N87 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method Inhibition of human HSP90 in NCI-N87 cells assessed as degradation of Her2 incubated for 24 hrs by Western blot method	[PMID: 22913511]
NCI-N87	IC₅₀	0.2 μM Compound: 28g, MPC-3100	Cytotoxicity against human NCI-N87 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human NCI-N87 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]
OVCAR-8	IC₅₀	0.49 μM Compound: 28g, MPC-3100	Cytotoxicity against human OVCAR8 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry Cytotoxicity against human OVCAR8 cells assessed as inhibition of tumor growth incubated for 72 hrs by luminometry	[PMID: 22913511]

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 958025-66-6
Appearance Solid
Molecular Weight 549.44
Formel C₂₂H₂₅BrN₆O₄S
Color White to off-white
SMILES

NC1=C2C(N(CCC3CCN(C([C@@H](O)C)=O)CC3)C(SC4=C(Br)C=C(OCO5)C5=C4)=N2)=NC=N1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5.5 mg/mL (10.01 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8200 mL

9.1002 mL

18.2003 mL

5 mM

0.3640 mL

1.8200 mL

3.6401 mL

10 mM

0.1820 mL

0.9100 mL

1.8200 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kim SH, et al. Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor. J Med Chem. 2012 Sep 13;55(17):7480-501. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8200 mL	9.1002 mL	18.2003 mL	45.5009 mL
	5 mM	0.3640 mL	1.8200 mL	3.6401 mL	9.1002 mL
	10 mM	0.1820 mL	0.9100 mL	1.8200 mL	4.5501 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MPC-3100

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle HSP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MPC-3100

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle HSP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MPC-3100 Related Classifications

HY-13301 Related Classifications